The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

Abstract Background Glioblastoma (GBM) is a fatal brain tumor, lacking effective treatment. Epidermal growth factor receptor (EGFR) is recognized as an attractive target for GBM treatment. However, GBMs have very poor responses to the first- and second-generation EGFR inhibitors. The third-generatio...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xuejiao Liu, Xiangyu Chen, Lin Shi, Qianqian Shan, Qiyu Cao, Chenglong Yue, Huan Li, Shengsheng Li, Jie Wang, Shangfeng Gao, Mingshan Niu, Rutong Yu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2019-05-01
Edice:	Journal of Experimental & Clinical Cancer Research
Témata:	GBM AZD9291 EGFR/ERK signaling pathway Cell proliferation
On-line přístup:	http://link.springer.com/article/10.1186/s13046-019-1235-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!